Cancer Innovations: Ossium Health's Cryopreserved Bone Marrow for Leukaemia

Thursday, 19 September 2024, 10:01

Cancer treatment is being revolutionized as Ossium Health successfully treats a leukaemia patient using cryopreserved bone marrow. The effectiveness of deep-frozen bone marrow from deceased organ donors is currently being evaluated in the ongoing PRESERVE I trial.
Pharmaceutical-technology
Cancer Innovations: Ossium Health's Cryopreserved Bone Marrow for Leukaemia

Cancer Advances through Cryopreserved Bone Marrow

Ossium Health has made significant strides in cancer treatment by successfully treating a leukaemia patient with cryopreserved bone marrow. This innovative approach utilizes deep-frozen bone marrow sourced from deceased organ donors, offering new hope for patients battling severe blood disorders.

The PRESERVE I Trial

The effectiveness and safety of this technique are currently under evaluation in the ongoing PRESERVE I trial. The research aims to provide greater insights into the potential of cryopreserved bone marrow as a viable treatment option.

  • Innovative Approach: Utilizing deceased donors ensures a broad availability of vital resources.
  • Patient-Centric Focus: Providing new treatment avenues for those with aggressive forms of leukaemia.
  • Future Potential: Cryopreserved bone marrow may offer solutions for other cancers in the future.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe